If you need more lookups,
subscriptions start at $34 USD/month.
Stephen Reece Location
London, GB
Stephen Reece Work
2024 -now Project Leader @
2022 -2024 Head of Infectious Diseases and Vaccines @
2021 -2022 Director, Antimicrobial Antibodies and Vaccines @
2017 -2021 Group Leader, Infectious Diseases and Vaccines @ Kymab Ltd
2016 -2017 Project Manager-Infectious Diseases @
2015 -2016 Project Manager, Centre for Genomic Pathogen Surveillance @
2013 -2015 Senior Project Manager, Translation and Development @
2012 -2013 Head of Vaccines @
2006 -2012 Senior Researcher and Team Leader @
2005 -2006 Scientist I @ Infectious Disease Research Institute
2002 -2005 Postdoctoral Fellow @ Infectious Disease Research Institute
1995 -1997 Research Assistant @
1993 -1995 Microbiologist @
Stephen Reece Education
Imperial College London
Doctor of Philosophy (PhD) (Molecular Biology)
1998-2002
London School of Hygiene and Tropical Medicine, U. of London
Master's degree (Infectious Diseases)
1997-1998
Imperial College London
Bachelor's degree (Biochemistry)
1990-1993
Stephen Reece Skills
Molecular Biology
Immunology
Cell Culture
Biochemistry
Life Sciences
Cell Biology
Lifesciences
Biotechnology
Project Management
Strategic Planning
Drug Discovery
Flow Cytometry
PCR
Cell
ELISA
Pharmaceutical Industry
Science
Infectious Diseases
Polymerase Chain Reaction (PCR)
Clinical Development
Polymerase Chain Reaction Pcr
Microsoft Excel
Customer Service
Polymerase Chain Reaction
Stephen Reece Summary
Stephen Reece, based in London, GB, is currently a Project Leader at CEPI (Coalition for Epidemic Preparedness Innovations). Stephen Reece brings experience from previous roles at Sanofi, Kymab Ltd and Cambridge University. Stephen Reece holds a 1998 - 2002 Doctor of Philosophy (PhD) in Molecular Biology @ Imperial College London. With a robust skill set that includes Molecular Biology, Immunology, Cell Culture, Biochemistry, Life Sciences and more. Stephen Reece has 2 emails on RocketReach.
Looking for a different Stephen Reece?
Find contact details for 700 million professionals.